Open-Angle Glaucoma Pipeline: Advancing Innovation with 18+ Leading Companies Developing Cutting-Edge Therapies | DelveInsight

The Open-Angle Glaucoma market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Nicox Ophthalmics, Betaliq, Qlaris Bio, Aerpio Pharmaceuticals, and Theratocular Biotek. These industry pioneers are transforming treatment strategies and redefining the future of Open-Angle Glaucoma, bringing new hope to patients worldwide.

DelveInsight's "Open-Angle Glaucoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Open-Angle Glaucoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Open-Angle Glaucoma drugs, the Open-Angle Glaucoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Open-Angle Glaucoma Pipeline Report
• DelveInsight's Open-Angle Glaucoma Pipeline analysis depicts a robust space with 18+ active players working to develop 20+ pipeline drugs for Open-Angle Glaucoma treatment.
• The leading Open-Angle Glaucoma companies include Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others are evaluating their lead assets to improve the Open-Angle Glaucoma treatment landscape.
• Key Open-Angle Glaucoma pipeline therapies in various stages of development include NCX 470, BTQ-1902, QLS-101, Razuprotafib, TO-O-1001, PA5108, WB-007, JV-GL1, Bremen, and others.
• In December 2024, Gland Pharma, a pharma company specializing in generic injectables, received approval from the FDA for its Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill). The approved product is bioequivalent and therapeutically equivalent to Xalatan, the reference listed drug held by UPJOHN US 2 LLC. Latanoprost Ophthalmic Solution is indicated for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
• In December 2024, Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced the submission of its New Drug Application (NDA) to the FDA for EPIOXA (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal disease.
• In May 2024, global pharmaceutical giant Lupin announced on May 6 that it secured approval from the FDA for its abbreviated new drug application (ANDA) for Travoprost Ophthalmic Solution USP, 0.004% (ionic buffered solution). Travoprost ophthalmic solution USP, 0.004%, is specifically indicated for the reduction of elevated intraocular pressure in patients diagnosed with eye conditions like open-angle glaucoma or ocular hypertension.

Request a sample and discover the recent breakthroughs happening in the Open-Angle Glaucoma pipeline landscape @ https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Open-Angle Glaucoma Overview
Open-angle glaucoma (OAG) is the most common form of glaucoma, marked by a gradual rise in intraocular pressure (IOP) due to partial blockage of the trabecular meshwork, despite the drainage angle remaining open. This pressure buildup damages the optic nerve over time, leading to irreversible vision loss. Often symptomless in its early stages, OAG is known as the "silent thief of sight."

Risk factors include age (40+), ethnicity (higher prevalence in African Americans, Hispanics, and Asians), family history, and conditions like diabetes, hypertension, and myopia. Corticosteroid use, eye injuries, and thin corneas also raise the risk.

Diagnosis involves measuring IOP, corneal thickness, and evaluating the drainage angle, with tools like OCT and visual field tests used to monitor nerve damage. Treatment aims to lower IOP via eye drops, oral medications, laser therapy, or surgery.

Regular eye exams and strict treatment adherence are crucial to slowing disease progression and preserving vision, as damage from OAG cannot be reversed.

Find out more about Open-Angle Glaucoma medication @ https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Open-Angle Glaucoma Treatment Analysis: Drug Profile
NCX 470: Nicox Ophthalmics
NCX 470 is an innovative second-generation nitric oxide (NO)-donating prostaglandin analog under development by Nicox Ophthalmics. Unlike traditional glaucoma treatments focused solely on lowering intraocular pressure (IOP), NCX 470 may also improve ocular perfusion, offering a potential dual benefit. Its mechanism combines NO donation with prostaglandin F2α activity, which early studies suggest could make it the most effective single-agent therapy for IOP reduction. NCX 470 is currently in Phase III clinical trials for the treatment of open-angle glaucoma and ocular hypertension.

BTQ-1902: Betaliq, Inc.
BTQ-1902 is a novel EyeSol-based formulation of timolol, a widely used beta blocker for glaucoma management. Beta blockers lower IOP by inhibiting sympathetic nerve activity in the ciliary epithelium, thereby reducing aqueous humor production. Often used in combination therapies, BTQ-1902 offers a promising approach with its advanced formulation. The drug is currently undergoing Phase II clinical trials for the treatment of open-angle glaucoma.

Key Open-Angle Glaucoma Therapies and Companies
• NCX 470: Nicox Ophthalmics
• BTQ-1902: Betaliq, Inc.
• TO-O-1001: Theratocular Biotek

Learn more about the novel and emerging Open-Angle Glaucoma pipeline therapies @ https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Open-Angle Glaucoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Open-Angle Glaucoma Pipeline Report
• Coverage: Global
• Key Open-Angle Glaucoma Companies: Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others.
• Key Open-Angle Glaucoma Pipeline Therapies: NCX 470, BTQ-1902, QLS-101, Razuprotafib, TO-O-1001, PA5108, WB-007, JV-GL1, Bremen, and others.

Dive deep into rich insights for drugs used for Open-Angle Glaucoma treatment; visit @ https://www.delveinsight.com/report-store/open-angle-glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Open-Angle Glaucoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Open-Angle Glaucoma Pipeline Therapeutics
6. Open-Angle Glaucoma Pipeline: Late-Stage Products (Phase III)
7. Open-Angle Glaucoma Pipeline: Late-Stage Products (Phase III)
8. Open-Angle Glaucoma Pipeline: Mid-Stage Products (Phase II)
9. Open-Angle Glaucoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.